1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The latest Pharmaceutical and Healthcare disease pipeline guide Kidney Transplant Rejection - Pipeline Review, H2 2020, provides an overview of the Kidney Transplant Rejection (Immunology) pipeline landscape.
Kidney transplantation is a therapy performed to replace a diseased kidney with a healthy kidney from another person. Risk factors associated with transplantation are bleeding, infection, blockage of the blood vessels to the new kidney, leakage of urine or blockage of urine in the ureter and initial lack of function of the new kidney. Treatment includes immunosuppressive drugs to prevent organ rejection.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Kidney Transplant Rejection - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Kidney Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Kidney Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 12, 9, 14, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.
Kidney Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Transplant Rejection (Immunology).
- The pipeline guide reviews pipeline therapeutics for Kidney Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Kidney Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Kidney Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Transplant Rejection (Immunology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Kidney Transplant Rejection (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Kidney Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Kidney Transplant Rejection - Overview
- Kidney Transplant Rejection - Therapeutics Development
- Kidney Transplant Rejection - Therapeutics Assessment
- Kidney Transplant Rejection - Companies Involved in Therapeutics Development
- Kidney Transplant Rejection - Drug Profiles
- Kidney Transplant Rejection - Dormant Projects
- Kidney Transplant Rejection - Discontinued Products
- Kidney Transplant Rejection - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Kidney Transplant Rejection, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Kidney Transplant Rejection - Pipeline by Alphamab Oncology, H2 2020
- Kidney Transplant Rejection - Pipeline by Amgen Inc, H2 2020
- Kidney Transplant Rejection - Pipeline by Amyndas Pharmaceuticals LLC, H2 2020
- Kidney Transplant Rejection - Pipeline by Astellas Pharma Inc, H2 2020
- Kidney Transplant Rejection - Pipeline by Bristol-Myers Squibb Co, H2 2020
- Kidney Transplant Rejection - Pipeline by Enceladus Pharmaceuticals BV, H2 2020
- Kidney Transplant Rejection - Pipeline by Genzyme Corp, H2 2020
- Kidney Transplant Rejection - Pipeline by Hansa Biopharma AB, H2 2020
- Kidney Transplant Rejection - Pipeline by Helocyte Biosciences Inc, H2 2020
- Kidney Transplant Rejection - Pipeline by Hillhurst Biopharmaceuticals Inc, H2 2020
- Kidney Transplant Rejection - Pipeline by Idogen AB, H2 2020
- Kidney Transplant Rejection - Dormant Projects, H2 2020
- Kidney Transplant Rejection - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Kidney Transplant Rejection, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Routes of Administration, H2 2020
- Number of Products by Stage and Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alphamab Oncology
- Amgen Inc
- Amyndas Pharmaceuticals LLC
- Astellas Pharma Inc
- Bristol-Myers Squibb Co
- Enceladus Pharmaceuticals BV
- Genzyme Corp
- Hansa Biopharma AB
- Helocyte Biosciences Inc
- Hillhurst Biopharmaceuticals Inc
- Idogen AB
- ITB-Med AB
- JN Biosciences LLC
- Junten Bio Co Ltd
- Kiniksa Pharmaceuticals Ltd
- Kronos Bio Inc
- Kyowa Kirin Co Ltd
- Lyndra Therapeutics Inc.
- Mabtech Ltd
- Medeor Therapeutics Inc
- MyeloRx LLC
- Nekonal Sarl
- NextCell Pharma AB
- Novartis AG
- OSE Immunotherapeutics
- Paranta Biosciences Ltd
- Pharmapraxis
- Rigel Pharmaceuticals Inc
- Sangamo Therapeutics Inc
- Talaris Therapeutics Inc
- TolerogenixX GmbH
- TRACT Therapeutics Inc
- Veloxis Pharmaceuticals AS
- Viela Bio Inc
